What does the new pediatric allergy spray actually add?
The new pediatric spray is a fixed-dose combination of an antihistamine (olopatadine) and a corticosteroid (mometasone), sold under brand names like Ryaltris. It's designed to tackle both the immediate sneezing and itching (antihistamine) and the underlying inflammation (corticosteroid) in one spray. In a 2022 randomized trial of 446 children aged 6–11 with seasonal allergic rhinitis, this combination significantly improved nasal symptoms compared to placebo—a 0.6-point drop on a 12-point symptom scale, which is a modest but real benefit [1]. It also improved quality of life, as measured by the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire, and was well tolerated, with side effects similar to placebo (12% vs 10.4%) [1].
But the key question is whether it beats what we already have. A 2025 network meta-analysis of 31 trials involving 12,168 children found that both intranasal corticosteroids (INCS) and the combination (INAH+INCS) were more effective than placebo for nasal symptoms, but the combination was not clearly superior to INCS alone [2]. In other words, the expansion gives doctors another effective option, but it doesn't replace the standard first-line treatment—a corticosteroid spray—for most kids.
Does the combination spray help eye symptoms more?
One area where the combination might have an edge is eye symptoms, which are common and bothersome in children with seasonal allergies. The 2022 trial found numerical improvements in eye symptoms favoring the combination, but only 'tearing/watering eyes' reached statistical significance (p=0.04) [1]. The 2025 meta-analysis also suggested that the combination had the highest probability of improving the Total Ocular Symptom Score compared to INCS alone, though neither was significantly better than placebo [2]. So the evidence is suggestive but not conclusive—if a child's main complaint is itchy, watery eyes, the combination might be worth trying, but it's not a guaranteed win.
Is it safe for long-term use in kids?
Safety is a top concern for parents, especially regarding growth suppression with corticosteroids. The 2022 trial reported only short-term (14-day) data, with no serious adverse events related to the treatment [1]. A 2022 Italian study of mometasone nasal spray (the corticosteroid component) in children found it was safe and well-tolerated over 3 weeks, and even reduced nasal inflammation (eosinophils and mast cells) [5]. However, long-term safety data in children remain sparse, as noted in a 2025 review [2]. The combination spray is approved for children 6 and older, but parents should discuss with their doctor if long-term use is needed, especially for younger kids.
When should a doctor choose the combination spray?
Given the evidence, the combination spray is a reasonable choice when a child has moderate-to-severe nasal symptoms that aren't controlled by a corticosteroid alone, or when eye symptoms are prominent. The 2025 meta-analysis found that combination therapy improved quality of life in seasonal allergic rhinitis, suggesting a role for children whose disease burden extends beyond just a stuffy nose [2]. However, it's not a first-line for everyone—the same analysis found no clear superiority over INCS for nasal symptoms [2]. Also, a 2025 Canadian review noted that while the combination improved symptoms vs placebo, it wasn't clearly better than mometasone alone in adults, and there was no comparative pediatric data [3]. So it's a tool, not a revolution—doctors should weigh the child's specific symptoms and preferences.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2025, 2 from 2024 or later, 2 in Q1 journals — selected as the most relevant from 5 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis
In a randomized, double-blind trial of 446 children aged 6–11 with seasonal allergic rhinitis, the olopatadine/mometasone combination spray significantly improved nasal symptoms vs placebo (0.6-point reduction on a 12-point scale) and was well tolerated, with similar adverse event rates to placebo.
Clearing the Air: Intranasal Therapies and the Evolving Evidence in Pediatric Allergic Rhinitis
A 2025 systematic review and network meta-analysis of 31 randomized trials (12,168 children) found that intranasal corticosteroids, antihistamines, and combinations all beat placebo for nasal symptoms, but combination therapy was not clearly superior to corticosteroids alone for nasal symptoms, though it showed the highest probability of improving eye symptoms.
Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Ryaltris)
A 2025 Canadian review of Ryaltris (olopatadine/mometasone) concluded that while it improved symptoms vs placebo in children, there was no comparative evidence vs active treatments in kids, and indirect evidence was too limited to determine if it offers added benefit over standard sprays.
Pollen-related food allergy in children with seasonalallergic rhinitis
A 2021 study of 43 children with pollen-food sensitization found that allergic rhinitis was the main symptom in 65.1%, and 25.6% had nasal symptoms triggered by eating pollen-related foods, highlighting the need to consider food triggers in pediatric seasonal rhinitis.
Mometasone furoate nasal spray in Italian children with seasonal allergic rhinitis: a comprehensive assessment
In an Italian study of children with seasonal allergic rhinitis, mometasone nasal spray significantly reduced nasal eosinophils and mast cells, improved quality of life, and relieved symptoms after 3 weeks, with effects persisting after discontinuation, and was safe.